Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ACTU

Actuate Therapeutics

ACTU Lead: Phase 2 17 Biotech Distilled articles ↓ 26 filings & releases ↓ Cash $4.4M (Jun 30, 2026) ↓ 17 verdicts ↓ 1 timing quote ↓
Oncology Small Molecule

Market cap $7.9M 24.0M shares (10-Q, Aug 13, 2026) × $0.329 close Nov 6, 2026

Most recent annual filing: 2026-01-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Elraglusib Ph3 start2H 2026Elraglusib Ph3 start, 2H 2026, routine
  2. Elraglusib Oral Tablet Ph1 start2H 2026Elraglusib Oral Tablet Ph1 start, 2H 2026, routine
  3. corporate listing updateJan 11, 2027corporate listing update, Jan 11, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$4.4M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$4.4M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$4.4M cash per the update of Oct 27, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (17)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (17 calls)

Every verdict Biotech Distilled has published on Actuate Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-07 Avoid Actuate Therapeutics (ACTU): Scientific Deep Dive for Elraglusib Financing overhang from $100M ATM, potential commercial dead end due to visual toxicity and inferior efficacy vs NALIRIFOX, and a Phase 2 win possibly driven by a weak control arm make this unattractive for new buyers.
  2. 2026-01-12 Hold UPDATE: Actuate Therapeutics (ACTU) — Finding Green Shoots in the Graveyard Pediatric data validates the mechanism and creates a PRV lottery ticket, but the business remains broken with financing overhang; fundamental investors should watch for a dip toward PRV-discounted value.
  3. 2026-01-13 Avoid UPDATE : Actuate Therapeutics (ACTU) Post-ASCO: The "Tail" Looks Real, but Is the Market is Blind? Strong 24-month survival tail validates the science, but the financing overhang from the ATM means good news creates dilution events rather than price appreciation; wait for a secondary offering or partnership announcement.
  4. 2026-01-25 Avoid Update : Actuate Therapeutics (ACTU) Goes Oral - A Lazarus Patient, A Pill, and An Empty Checkbook The oral tablet announcement broadens the narrative but does not solve the solvency challenge; the $100M ATM looms and every new press release is a menu of unfunded ambitions.
  5. 2026-03-15 Avoid UPDATE: Actuate Therapeutics (ACTU) - A Great Science Project Doesn't Pay the Bills A preclinical RAS combination initiative is scientifically sound but does not fund the registrational trial; the dilution gap remains and press releases are window dressing on a burning building.
  6. 2026-03-29 Avoid UPDATE: Actuate Therapeutics (ACTU) - The "Going Concern" Ghost and the July 2026 Cliff Annual report formalizes going-concern doubt with a July 2026 cash cliff and $100M ATM locked and loaded; a great molecule trapped in a broken balance sheet is a recipe for heavy losses.
  7. 2026-04-27 Hold UPDATE: Actuate Therapeutics (ACTU) - Nature Medicine Blesses the Sledgehammer Nature Medicine peer-reviewed validation materially weakens the weak-control-arm bear case and raises partnership probability, but the July 2026 cash cliff is unchanged so a full buy is not warranted.
  8. 2026-05-12 Watch UPDATE: Actuate Therapeutics (ACTU) - The Mersana Guy Just Joined the Board Huber's M&A pedigree and the oral IND clearance strengthen the BD/partnership narrative, but the cash cliff is ~60-90 days away so the primary stance is to accumulate only on weakness rather than chase the current tape.
  9. 2026-06-01 Watch UPDATE: Actuate Therapeutics (ACTU) - The KRAS Wild-Type Tell ASCO biomarker data showing a 7-month mOS swing in KRAS WT patients sharpens the BD pitch, but the stock is down 33% with ~8 weeks to the July cash cliff and no partnership announced; asymmetry is more extreme in both directions.
  10. 2026-06-09 Watch UPDATE: Actuate Therapeutics (ACTU) - Someone Else Is Paying for the Neuroblastoma Trial Cancer Research UK funding the BEACON2 neuroblastoma trial is a capital-efficient win for the PRV plan-B path, but the pancreatic/financing binary is unchanged with ~6 weeks to the July cliff.
  11. 2026-07-17 Avoid UPDATE: Actuate Therapeutics (ACTU) - The Second Clock Just Started Nasdaq MVLS deficiency notice adds a second independent clock to the going-concern pressure, counterparty leverage in any BD conversation has shifted toward buyers, and the risk-adjusted odds have deteriorated on the same underlying science.
  12. 2026-08-15 Avoid UPDATE: Actuate Therapeutics (ACTU) - $4.4 Million and Six Weeks Q2 10-Q reveals only $4.4M cash with a September 2026 runway, the going-concern is now genuinely distressed, and waiting for the financing or deal announcement before buying appears better-compensated.
  13. 2026-09-10 Avoid UPDATE: Actuate Therapeutics (ACTU) - The Revolution Medicines Audition Preclinical synergy data with RAS(ON) inhibitors is the sharpest BD pitch yet but is dish-and-mouse data with no p-values; the equity still faces an unpriced financing event with ~one quarter of cash remaining.
  14. 2026-10-07 Avoid UPDATE: Actuate Therapeutics (ACTU) - The Dilution Finally Arrives The S-1 for 50M shares at ~$0.82 triples the share count at distressed terms, funds survival not a Phase 3, and signals no partnership term sheet is imminent; wait until after pricing to reconsider.
  15. 2026-10-15 Avoid UPDATE: Actuate Therapeutics (ACTU) - The Deal Is Chasing the Stock Down Amendment No. 1 upsizes to 65M shares at an assumed $0.6437 already 33% above market, net proceeds could come in well under assumption, and the MVLS cure no longer works at today's price.
  16. 2026-10-20 Avoid UPDATE: Actuate Therapeutics (ACTU) - Half the Shares, Half the Cash, Plus Warrants Amendment No. 2 cuts to 40M shares at $0.50 with half-warrant coverage, raising only ~$18.3M net — roughly one year of runway — while adding a 25M+ warrant overhang and leaving the Phase 3 unfunded.
  17. 2026-10-28 Avoid UPDATE: Actuate Therapeutics (ACTU) - Priced at 35.5 Cents Final pricing at $0.355/share raised only ~$11M gross — about two quarters of runway — with a $0.45 warrant ceiling just above the stock, the Phase 3 still unfunded, and Nasdaq compliance further away than ever.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)